KOREA WHO

Seo Jung-jin is the Chairman of Celltrion Group. He is the largest shareholder of Celltrion Holdings, the holding company of Celltrion.

Although he stepped down from management, announcing the establishment of a professional management system in Celltrion Group, he declared his return to management in March 2023 and took on the role of Chairman of the Board.

While promoting the merger of the three Celltrion companies, he presented a blueprint to achieve KRW 12 trillion (US$ 8.7 billion) in sales by 2030 through the launch of new biosimilar products and the development of new drugs.

He was born on October 23, 1957, in Cheongju, Chungcheongbuk-do.

He graduated from Konkuk University with a degree in Industrial Engineering and received a master's degree in Business Administration from Konkuk University Graduate School.

He began his career at Samsung Electro-Mechanics. He then moved to the Korea Productivity Center, where he consulted for Daewoo Motors and caught the attention of Kim Woo-jung, the former Chairman of Daewoo Group, working as a Planning and Finance Advisor for Daewoo Motors.

After losing his job during the financial crisis, he founded Nexol, the predecessor of Celltrion, with about 10 colleagues from Daewoo Motors.

He is targeting the global market through Celltrion Healthcare, established for the purpose of overseas sales of biosimilars.

When COVID-19 spread globally, he developed COVID-19 treatments and diagnostic kits.

After stepping down from management in 2020, he ventured into the healthcare business related to blood tests.

He is known for his excellent ability to grasp the core of issues and his active approach. When things do not go well, he goes to the field himself to find clues to solve problems.

He enjoys his work so much that he counts overseas business trips as a hobby.

#Celltrion #SeoJungjin #biosimilar #biopharmaceutical #COVID19 #KoreanBusiness #merger #globalmarket #healthcare #businessleadership